Alar Pharmaceuticals Inc.
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating t… Read more
Alar Pharmaceuticals Inc. (6785) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: -0.011x
Based on the latest financial reports, Alar Pharmaceuticals Inc. (6785) has a cash flow conversion efficiency ratio of -0.011x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-26.60 Million) by net assets (NT$2.48 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Alar Pharmaceuticals Inc. - Cash Flow Conversion Efficiency Trend (2020–2023)
This chart illustrates how Alar Pharmaceuticals Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Alar Pharmaceuticals Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alar Pharmaceuticals Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
J.Kumar Infraprojects Limited
NSE:JKIL
|
0.129x |
|
Grupo Clarin S.A.
BA:GCLA
|
0.050x |
|
NanJing Sanchao Advanced Materials Co Ltd
SHE:300554
|
-0.061x |
|
Giordano International Limited
PINK:GRDZF
|
0.212x |
|
Marr S.p.A.
LSE:0NSS
|
-0.123x |
|
Healius Ltd
AU:HLS
|
0.162x |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
N/A |
|
Chongqing Yukaifa Co Ltd
SHE:000514
|
0.003x |
Annual Cash Flow Conversion Efficiency for Alar Pharmaceuticals Inc. (2020–2023)
The table below shows the annual cash flow conversion efficiency of Alar Pharmaceuticals Inc. from 2020 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | NT$897.12 Million | NT$403.57 Million | 0.450x | +802.49% |
| 2022-12-31 | NT$514.50 Million | NT$-32.95 Million | -0.064x | +46.09% |
| 2021-12-31 | NT$534.37 Million | NT$-63.47 Million | -0.119x | +49.90% |
| 2020-12-31 | NT$598.60 Million | NT$-141.92 Million | -0.237x | -- |